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Short Communication
In vivo Binding Behavior of Dopamine Receptor Agonist (+)-PD
128907 and Implications for the “Ceiling Effect” in Endogenous
Competition Studies with [11C]raclopride—a Positron Emission
Tomography Study in Macaca mulatta
*Rudie Kortekaas, *R. Paul Maguire, †Thomas I. Cremers, †Durk Dijkstra, ‡Aren van Waarde
and *Klaus L. Leenders
Summary: In in vivo positron emission tomography (PET)
studies, dopamine that is released secondary to amphetamine
administration appears unable to achieve a receptor occupancy
that is significantly higher than 50% (“ceiling effect”). Also
with exogenous agonists no studies have reported a higher
than 50% occupancy. To investigate the feasibility of exceed-
ing 50% occupancy in vivo with a dopamine receptor agonist
we administered D2/D3 agonist (+)-PD 128907 over an ex-
tensive dose range. Two anesthetised Macaca mulatta males
were used in a bolus-infusion protocol for [11C]raclopride. (+)-
PD 128907 was administered as an intravenous challenge dur-
ing separate PET scans in a dose range of 10 to 10000 nmol/kg.
Occupancy by (+)-PD 128907 was estimated by comparing the
binding before and after challenge. In a striatal region of inter-
est, receptor occupancy by (+)-PD 128907 increased in an or-
derly dose-dependent manner to a maximum of at least
85%. This is the first indication that virtually all dopamine
D2/D3 receptors in the striatum are in principle accessible to
agonist binding. In the case of dopamine a number of protective
mechanisms may be responsible for the ceiling effect. Key
Words: Monkey—PET—Dopamine—D2-like receptors—
Brain—[11C]raclopride.
The PET tracer [11C]raclopride is a benzamide antago-
nist for dopamine D2 and D3 receptors. Like other benza-
mide and catecholamine tracers, [11C]raclopride binding
is sensitive to occupancy by other receptor ligands in a
way that is consistent with the occupancy model i.e.
binding is reduced when competing ligands such as do-
pamine are present (Laruelle 2000). For this reason
[11C]raclopride is often applied to study dynamic
changes in brain dopamine concentrations. Many studies
have used dopaminergic manipulations that increase
dopamine concentration. The amphetamines d-amphet-
amine, d-methamphetamine and d-methylphenidate
cause an increase in dopamine concentration in the brain
and a reduction in [11C]raclopride binding (Dewey et al.,
1993; Volkow et al., 1994; Tsukada et al., 1999).
The ceiling effect entails that even high dosages of
amphetamines do not reduce [11C]raclopride binding by
more than 50% (Laruelle 2000). Laruelle has suggested
three possible contributing phenomena for this observa-
tion: i) 50% of receptors being extrasynaptic, ii) the low
efficiency of dopamine, being an agonist, in occupying
low affinity state receptors and iii) basal occupancy by
dopamine (Laruelle 2000).
In vitro, the ceiling effect does not exist as such. E.g.
the dopamine D2/D3 receptor agonist (+)-PD 128907
completely displaces the dopamine antagonist [3H]spi-
perone from dopamine D2 and D3 receptors on mem-
brane fractions, despite the presence of the non-
hydrolysable GTP analogue GppNHp in the medium,
which favors the low affinity state. In this case the dis-
placement curve is ‘shallow’ with an apparent Hill co-
efficient of less than unity (Pugsley et al., 1995).
In vivo binding behavior of exogenous agonists could
indicate whether something fundamental is limiting
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agonist binding to 50% and clarify the relative contribu-
tion of phenomena i) and ii). If phenomenon i) plays a
key role in the ceiling effect, the ceiling effect should not
apply to exogenous dopamine receptor agonists since
they are expected to reach similar intra- and extrasynap-
tic concentrations. Binding is expected to be complete
and without evidence for multiple sites. If phenomenon
ii) was to play the main role in the ceiling effect, exog-
enous dopamine agonists are also expected to reach
100% occupancy, but with a “shallow” or two-step as-
sociation curve.
Experiments with exogenous agonists have not found
occupancy of dopamine receptors in excess of 50% as
measured with benzamide radiotracers for PET or SPECT.
E.g. the binding of [123I]-iodobenzamide was reduced by
≈5% in parkinsonian patients treated with dopamine ago-
nists pramipexole or lisuride (Schwarz et al., 1996) and
by 45% in parkinsonian monkeys treated with the dopa-
mine agonist LY 171555 (Vermeulen et al., 1994).
However, since these studies have not used extensive
dose ranges, it is unclear what type of association behav-
ior occurs between dopamine agonists and dopamine re-
ceptors in vivo. To obtain this information we adminis-
tered escalating dosages of D2/D3 agonist (+)-PD 128907
(Dijkstra et al., 1988) while measuring free D2/D3 recep-
tors with [11C]raclopride and PET.
METHODS
Subjects
Two adult male rhesus monkeys (5.5 to 8 kg) were used.
(±)-Ketamine was administered for handling, transportation
and anesthetic induction. Two intravenous cannulae were in-
serted, one for administration of tracer and (+)-PD 128907, the
other for blood sampling. Atropine (0.06 to 0.09 mg/kg intra-
muscular) and sodium pentobarbital (8 to 11 mg/kg intrave-
nous) were administered, the trachea was intubated for venti-
lation with isoflurane (1 to 2% (v/v)) in a carrier gas mixture of
O2:N2O 50:50. Heart rate, electrocardiogram, respiration rate
and O2 saturation were monitored throughout the experiment.
Drugs and tracer administration
The hydrochloride salt of (+)-PD 128907 was synthesized as
described before (Dijkstra et al., 1988). Unlabeled raclopride
and domperidone were obtained from RBI (Natick, U.S.A.).
The tracer [11C]raclopride was synthesized by [11C] meth-
ylation of the hydroxy-precursor (Farde et al., 1988). A total of
63 to 203 MBq of activity was dissolved in 20 mL sterile 0.9%
saline, and taken to the subject in the PET scanner.
At t 0 minutes, over the first 60 seconds of the acquisition,
a tracer volume corresponding to 83 minutes of infusion (60 for
the studies at 0 nmol/kg) was injected. Immediately after
completion of the bolus the infusion was started.
At t  15 minutes, domperidone (200 g/kg, intravenous)
was administered to block peripheral dopamine D2/D3 recep-
tors. This treatment was included after noting cardiovascular
effects of (+)-PD 128907 at the highest dose. The studies at
0 and 10000 nmol/kg were performed without domperidone
pretreatment.
At t  45 minutes, an intravenous challenge of (+)-PD
128907 was injected over 60 seconds. Monkey 1 received 0
(three times) and 10000 nmol/kg, monkey 2 received 1.0; 3.2;
10; 31.6; 100; 316; 562; 1000 and 3162 nmol/kg. The dose of
31.6 was repeated, since on the first occasion the binding of
[11C]raclopride was still rising at the time of challenge. All
studies were included in the displacement curve.
Scanning procedures
The monkey was positioned in a stereotaxic frame (all stud-
ies except the very first one at 0 nmol/kg) in an ECAT HR+
PET scanner (Siemens, Erlangen, Germany). The field of view
included the entire brain and part of the thorax.
A 20-minute transmission scan was performed for attenua-
tion correction. There was always a minimum of 13 days be-
tween two consecutive scans in the same monkey.
After the experiments at 0 and 10000 nmol/kg which used 6
x 2.5, 6 x 5, 6 x 2.5 and 6x5 minutes frame durations, scanning
duration and temporal resolution were increased to 48 x 2.5
minutes. In the cases where frame duration was 5 minutes the
time activity curves and binding ratio curves were interpolated.
Reconstruction was performed to a 128 x 128 x 63 matrix with
a plane separation of 0.2425 cm and a bin size of 0.2250 cm.
Data analysis
A region of interest analysis was performed with Clinical
Applications Programming Package 5 (Siemens, Erlangen,
Germany) for the striatum and the cerebellum. Binding ratio
was defined as (striatal activity - cerebellar activity) / cerebellar
activity. Under equilibrium conditions the binding ratio equals
the binding potential.
The binding ratio in absence of (+)-PD 128907 was calcu-
lated for the striatal ROIs by averaging the binding ratio over
nine frames before the 45 minute point.
For every PET experiment, the minimum in the binding ratio
due to displacement was located by a second degree polyno-
mial fit on the curve after (+)-PD 128907 administration. This
was expressed relative to plateau and plotted against dose of
(+)-PD 128907. The resulting curve was fitted with a logistic 4
parameter fit by SigmaPlot (v7.0, SPSS Inc., Chicago, U.S.A.).
The parameters were: Bmin, Bmax, ED50 and nH. The parameter
nH is the Hill coefficient which, if significantly different from
unity, indicates a deviation from single site, non-cooperative
binding behavior. Its absolute value cannot exceed the number
of binding sites for a ligand (Monod et al., 1965).
RESULTS
Over the separate experiments, increasing dosages of
(+)-PD 128907 were injected to occupy dopamine D2/D3
receptors as measured with infused [11C]raclopride.
Figure 1 shows the curves for binding ratio for
[11C]raclopride in time. At the three highest dosages of
(+)-PD 128907, there was an evident reduction in bind-
ing ratio, that was larger when the (+)-PD 128907 dose
was larger. After 1000 nmol/kg there was partial recov-
ery towards the baseline binding ratio, but at the highest
two dosages this did not occur. At the highest dose of
(+)-PD 128907 the binding ratio was reduced almost
to zero.
The fitted minimum values of the curves in Fig. 1 are
plotted against dose of (+)-PD 128907 in Fig. 2. This is
thus the minimum relative binding ratio due to (+)-PD
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128907 injection against the dose. There clearly is an
orderly dose dependent decrease in minimum binding
ratio for [11C]raclopride. When the data were fitted with
three different 4-parameter logistic fits (unconstrained,
constrained to Bmin  0%, constrained to Bmax 
100%), all three fits described the data well. Judging by
the correlation coefficient R, none of the fits was supe-
rior to the others. Table 1 provides the parameter esti-
mates from the three fits. The data did not support re-
jection of the hypotheses Bmax 100%, Bmin 0% and
nH  1.000.
DISCUSSION
The highest dose of the dopamine agonist (+)-PD
128907 reduced specific binding of [11C]raclopride in
the striatum by at least 85%. The shape of the binding
ratio curve after 10000 nmol/kg (+)-PD 128907 (Fig. 1
bottom right) suggests that measuring for longer would
show an even larger decrease. This is a much larger
effect than that reported with dopamine releasers, so that
the “ceiling effect” of 50% does not apply to (+)-PD
128907. Provided that (+)-PD 128907 acts in vivo as an
agonist and [11C]raclopride as an antagonist at dopamine
D2/D3 receptors, these data prove that no fundamental
mechanism is restricting agonist binding to  50%.
The sigmoidal curve in Fig. 2 did not display overt
two-step behavior, nor was the apparent Hill slope (nH)
significantly different from unity. This means that the
present data (from twelve PET scans) do not have suf-
ficient statistical power to prove heterogeneity of the
receptor population that [11C]raclopride and (+)-PD
128907 bind to. Hence there is no evidence in favor of a
FIG. 2. Displacement of [11C]raclopride by (+)-PD 128907. The
minimum relative binding ratio for [11C]raclopride is plotted
against dose of (+)-PD 128907. The line represents a 4-param-
eter logistic fit constrained to a Bmax of 100%.
FIG. 1. Binding ratio in time (min) for different dosages of (+)-PD 128907.
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multiple sites model representing e.g. high and low af-
finity receptors or the D2 and D3 subtype (both [11C]ra-
clopride and (+)-PD 128907 have relatively high affinity
(Kd≈1nM) for dopamine D3 receptors).
Since the ceiling effect, as seen with dopamine release
secondary to amphetamine, does not apply to (+)-PD
128907, it could be caused by extrasynaptic dopamine
levels not rising sufficiently to occupy extrasynaptic re-
ceptors which do remain available for antagonist tracer
binding. These dopamine levels are limited by reuptake,
degradation and the available intracellular dopamine
pool, and it appears likely that the brain has efficient
mechanisms to prevent maximal agonistic stimulation.
Since (+)-PD 128907, like [11C]raclopride but unlike do-
pamine, is expected to have full access to extrasynaptic
receptors the former two compounds compete for the
same receptors. Another possibility could be that am-
phetamine is in fact able to cause 100% occupancy by
dopamine of D2/D3 receptors, but does so only at a toxic
dose level. If one constructs a displacement curve for
published primate studies with the amphetamines it be-
comes clear that a ≈50% reduction in [11C]raclopride
binding occurs over a dose range of about one order of
magnitude. This is not inconsistent with a maximal effect
size of 100%, although not enough is known about this
relationship to make a reliable extrapolation.
In the present study the mean basal binding ratio was
1.1, which is lower than in similar studies reported in the
literature, e.g. (Ito et al., 1998; Tsukada et al., 2002).
This may be partly due to the partial volume effect and
a relatively large size of the regions of interest. Anes-
thesia may also play a role since this is known to lower
the binding of [11C]raclopride (Tsukada et al., 2002). In
particular ketamine, which our animals received twice,
could be the cause of this since it has been found to
reduce [11C]raclopride binding (Vollenweider et al.,
2000). However, none of these issues influence the main
finding that the agonist (+)-PD 128907 was able to oc-
cupy a very large portion of the receptor ensemble.
After 1000 nmol/kg of (+)-PD 128907 the time activ-
ity curve and binding ratio curve (Fig. 1) recovered to-
wards basal, presumably as the compound was cleared
from the blood and brain. This recovery was much faster
than that seen after amphetamine administration, where
tracer binding remains reduced for hours (Laruelle et al.,
1997; Laruelle 2000). In the case of amphetamine, ago-
nist induced internalization of dopamine receptors (La-
ruelle 2000) together with an inability of raclopride to
reach these internalized receptors (Sun et al., 2003) has
been postulated to explain the lasting reduction.
In summary, the ceiling effect of 50% dopamine re-
ceptor occupancy does not apply to the exogenous ago-
nist (+)-PD 128907. Thus there is no reason to assume
that dopamine can not in principle bind to low affinity
D2/D3 receptor sites. The ceiling effect as noted with
amphetamines could be caused by (extracellular) dopa-
mine concentrations being limited by available dopa-
mine pools, uptake and degradation mechanisms and tox-
icity issues.
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